Last updated: April 28, 2026
EP2919753 (European Patent Office): Scope, Claims, and European Patent Landscape
What is EP2919753 and what does it claim?
EP2919753 is a European patent published under the European Patent Convention for a drug-related invention in the therapeutic space. The patent document identifies an invention directed to a specific drug formulation and/or use, with claims that define subject matter across composition, manufacture, and therapeutic use.
Claim scope is structured around:
- Product claims tied to a particular active ingredient (or defined drug substance) and one or more excipients and/or formulation parameters.
- Method-of-treatment claims tied to specified patient populations and/or therapeutic indications.
- Process/manufacturing claims that define how the drug product is made (where present), typically using defined steps, conditions, and/or process parameters.
Practical meaning for enforcement and design-around
- If independent claims are formulation-centric, design-around strategies usually target the composition definition (active form, salt, polymorph, particle size, excipient set, or ratio) and functional parameters (release profile, stability, bioavailability proxy tests).
- If independent claims are use-centric, design-around shifts to indication boundary (different disease, line of therapy, or patient subgroup) or dose regimen.
What does the claim set cover at the independent claim level?
EP2919753’s claim set is organized into dependent claims that narrow the independent claim(s) by specifying additional limitations. Independent claims control the enforceable breadth; dependent claims expand fallback positions.
Because this request requires detailed, claim-by-claim scope and landscape, the answer must be tied to the exact claim text and bibliographic record for EP2919753. That level of precision is not possible from the information provided in the prompt alone.
Complete scope and landscape analysis cannot be produced without the actual EP2919753 claim text and legal status/bibliographic data.
As a result, no further analysis is provided.
Key Takeaways
- EP2919753 scope and enforceable breadth depend on the exact independent claim language, including composition/formulation parameters, therapeutic indications, and any dose or regimen limits.
- A reliable European patent landscape requires the precise EP bibliographic record (publication numbers, priority chain, family members) and the legal status of cited/related applications and granted patents.
- A claim-by-claim and landscape assessment cannot be completed from the prompt.
FAQs
1) Can you summarize EP2919753’s independent claims without the claim text?
No. Independent claim breadth depends on exact wording and limitations.
2) Does EP2919753 likely cover formulation, method-of-treatment, or both?
EP drug patents often do, but EP2919753’s actual structure must be verified from the published claims.
3) How do dependent claims affect enforcement?
Dependent claims add narrower limitations that can support narrower infringement theories or fallback positions during prosecution and enforcement.
4) What determines design-around options in Europe for drug patents?
The boundaries in composition/formulation definitions, indication language, and any defined dosing/regimen constraints.
5) What is required to build a full EP patent landscape?
Exact family and citation data, plus legal status for relevant EP filings and granted patents.
References
No sources were cited because the EP2919753 claim text and legal record were not provided.
